Business Context and Reporting Period
This Form 8-K, dated January 18, 2019, reports that Bristol-Myers Squibb Company entered into a Term Loan Agreement to finance the proposed merger with Celgene Corporation. The filing details the execution of a definitive financing agreement intended to replace a portion of a previously announced bridge facility.
Key Financial Metrics and Debt Structure
The Term Loan Agreement establishes total commitments of $8.0 billion, reducing the prior $33.5 billion bridge facility. The facility is unsecured and structured into three tranches:
- $1.0 billion 364-day tranche: Non-amortizing; matures on the 364-day anniversary of the Closing Date.
- $4.0 billion three-year tranche: Non-amortizing; matures on the third anniversary of the Closing Date.
- $3.0 billion five-year tranche: Amortizes at 0.0% annually for the first three years, then 10% per annum for the final two years; matures on the fifth anniversary.
Interest rates are variable, based on either a Base Rate or Eurodollar Rate plus an applicable margin ranging from 0.0% to 1.375%, dependent on the company's credit ratings. Borrowings are pre-payable without premium or penalty, subject to breakage costs.
Material Changes and Conditions
The primary material change is the reduction of the $33.5 billion bridge facility commitments by $8.0 billion following the execution of this Term Loan Agreement. Funding of the loans is contingent upon the satisfaction or waiver of several conditions, including:
- Completion of the Merger with Celgene.
- Non-occurrence of a material adverse effect on Celgene.
- Accuracy of representations and warranties for both companies.
- Absence of defaults by Bristol-Myers Squibb.
- Delivery of required financial statements.
Outlook, Risks, and Contingencies
Management commentary indicates that the transaction is subject to significant uncertainties. The filing includes extensive forward-looking statements regarding the anticipated benefits of the acquisition, synergy realization, and future capital structure. Key risks identified include:
- Failure to satisfy closing conditions or obtain necessary regulatory approvals.
- Inability to achieve projected synergies or successfully integrate Celgene's business.
- Potential decline in credit ratings for the combined company.
- Disruption to business operations and retention of key personnel.
- Changes in governmental regulations, pricing pressures, and patent expirations.
The filing explicitly states that projected financial information has not been prepared in conformance with Regulation S-X and should not be considered a substitute for historical financial statements.
Investor Verification Checklist
- Verify the final closing date of the Merger and the subsequent funding of the $8.0 billion term loans.
- Monitor the company's credit ratings to determine the specific applicable interest rate margins.
- Review the upcoming joint proxy statement/prospectus (Form S-4) for detailed pro forma financial information and risk factors.
- Track the status of regulatory approvals required for the Celgene acquisition.
- Assess the impact of the $8.0 billion debt addition on the combined company's leverage ratios and liquidity position.